Indium lung—case reports and epidemiology

  • Kazuyuki Omae
  • Makiko Nakano
  • Akiyo Tanaka
  • Miyuki Hirata
  • Tsutahiro Hamaguchi
  • Tatsuya Chonan



The present review is aimed to introduce an new occupational lung disease, Indium Lung.


We searched case reports and epidemiological studies concerning indium-related lung diseases and reviewed.


Up to March, 2010, 7 cases of interstitial pneumonia in Japanese indium-exposed workers, two cases of pulmonary alveolar proteinosis (PAP) in US indium-exposed workers, one case of PAP in a Chinese indium-exposed worker, and 4 cross-sectional surveys in Japan had been published. All cases and epidemiological studies in Japan indicate that exposure to hardly soluble indium compounds causes interstitial as well as emphysematous lung damages, which we call “Indium Lung”. Based on the epidemiological studies, the Japan Society for Occupational Health proposed 3 μg/l of indium in serum as an occupational exposure limit based on biological monitoring to prevent significant increase of KL-6.


Long-term follow-up of currently and formerly indium-exposed workers is essential not only to clarify the natural history of indium lung but also to trace the incidence of lung cancer. It is also necessary to elucidate the mechanism of indium lung and difference in clinical manifestations between Japanese and US cases.


Indium Occupational exposure Interstitial lung disease KL-6 SP-D 


Conflict of interest



  1. American Conference of Governmental Industrial Hygienists (ACGIH) (2001) Documentation of the threshold limit values and biological exposure indices, 7th edn. American Conference of Governmental Industrial Hygienists, CincinnatiGoogle Scholar
  2. Chonan T, Taguchi O, Omae K (2007) Interstitial pulmonary disorders in indium-processing workers. Eur Respir J 29:317–324CrossRefGoogle Scholar
  3. Cummings KJ, Walter E, Donat WE, Ettensohn DB, Roggli VL, Ingram P, Kreiss K (2010) Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 181:458–464CrossRefGoogle Scholar
  4. Hamaguchi T, Omae K, Tanaka A, Hirata M, Takebayashi T, Kikuchi Y, Yoshioka N, Nishiwaki Y, Taguchi O, Chonan T (2008) Exposure to hardly soluble indium compounds in the ITO producing and recycling plants is a new potent risk of interstitial lung damage. Occup Environ Med 65:51–55CrossRefGoogle Scholar
  5. Homma T, Ueno T, Sekizawa K, Tanaka A, Hirata M (2003) Interstitial pneumonia developed in a worker dealing with particles containing indium-tin oxide. J Occup Health 45:137–139CrossRefGoogle Scholar
  6. Homma S, Miyamoto A, Sakamoto S, Kishi K, Motoi N, Yoshimura K (2005) Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide. Eur Respir J 25:200–204CrossRefGoogle Scholar
  7. Japan Society for Occupational Health (2007) Documentation of occupational exposure limit of indium and compounds based on biological monitoring. San Ei Shi 45:137–139 (in Japanese)Google Scholar
  8. Minami H (2010) Trend of demand, supply and price of indium and gallium. Kinzoku-Shigen Report (May), 81–93. (in Japanese)Google Scholar
  9. Nakano M, Kamata H, Saito F, Tanaka A, Hirata M, Ishizaka A, Omae K (2007) A case of indium lung disclosed in health checkup. Occup Health J 30:25–29 (in Japanese)Google Scholar
  10. Nakano M, Omae K, Tanaka A, Hirata M, Kikuchi Y, Yoshioka N, Nishiwaki Y, Chonan T (2009) Causal relationship between indium compound inhalation and effects on the lungs. J Occup Health 51:513–521CrossRefGoogle Scholar
  11. National Toxicology Program (2001) Toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-90-7) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser 499:7–340Google Scholar
  12. Nogami N, Shimoda T, Shoji S, Nishima S (2008) Pulmonary disorders in indium-processing workers. J Jpn Respir Soc 46:60–64 (in Japanese)Google Scholar
  13. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165:378–381Google Scholar
  14. Taguchi O, Chonan T (2006) Three cases of indium lung. J Jpn Respir Soc 44:532–535 (in Japanese)Google Scholar
  15. Takeuchi K (2008) Pulmonary toxicity of indium. Kokyuu 27(6):599–603 (in Japanese)Google Scholar
  16. Tanaka A, Hirata M, Kiyohara Y, Nakano M, Omae K, Shiratani M, Koga K (2010) Review of pulmonary toxicity of indium compounds to animals and humans. Thin Solid Films 518:2934–2936CrossRefGoogle Scholar
  17. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF (2004) High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patientswith idiopathic pulmonary alveolar proteinosis. Blood 103:1089–1098CrossRefGoogle Scholar
  18. U.S. DHEW (1964) Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. Public Health Service Publication No. 1103. Washington, DCGoogle Scholar
  19. Xiao YL, Cai HR, Wang YH, Meng FQ, Zhang DP (2010) Pulmonary alveolar proteinosis in an indium-processing worker. Chin Med J 123:1347–1350Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Kazuyuki Omae
    • 1
  • Makiko Nakano
    • 1
  • Akiyo Tanaka
    • 2
  • Miyuki Hirata
    • 2
  • Tsutahiro Hamaguchi
    • 1
  • Tatsuya Chonan
    • 3
  1. 1.Department of Preventive Medicine and Public HealthSchool of Medicine, Keio UniversityTokyoJapan
  2. 2.Department of Hygiene, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of MedicineNikko Memorial HospitalHitachiJapan

Personalised recommendations